CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma

Nearly three years after treatment with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel), the risk of death was reduced by 45% compared with standard of care.

Orca-T immunotherapy reduces GVHD over conventional allogeneic HSCT

Orca-T is an allogeneic stem cell and T-cell immunotherapy that leverages high-purity regulatory T cells to prevent GVHD.